Gustave Roussy, Cancer Campus, Grand Paris
Clinical trials sponsored by Gustave Roussy, Cancer Campus, Grand Paris, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can vitamin a derivative shield immune system during cancer radiation? Results expected Sep 2026 (estimated)
- Glow-in-the-Dark dye could help surgeons see hidden cancer cells Results expected Nov 2026 (estimated)
- Less surgery may be enough for Low-Risk thyroid cancer Results expected Dec 2026 (estimated)
- Immunotherapy combo may keep rare head and neck cancer at bay Results expected Jan 2027 (estimated)
- New care pathway aims to ease cancer Patients' distress Results expected Jan 2027 (estimated)
-
Can a cancer drug stall advanced lung cancer?
Disease control Stopped earlyThis phase II trial is testing whether bortezomib, a drug that interferes with cancer cell growth, can help people with advanced non-small cell lung cancer. Participants have stage IIIB or IV disease and have not received prior chemotherapy. The main goal is to see if the drug ca…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Chemo-Radio duo slow advanced prostate cancer?
Disease control Stopped earlyThis trial is testing whether combining the chemotherapy drug docetaxel with a radioactive agent called samarium can help men with advanced prostate cancer that has stopped responding to hormone therapy. Participants are men aged 18 to 80 who have bone metastases and whose diseas…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Radiation and immunotherapy join forces against hard-to-treat liver cancer
Disease control Stopped earlyThis trial tests whether adding a precise, internal radiation treatment (166Holmium microspheres) to standard immunotherapy (atezolizumab and bevacizumab) can shrink liver tumors that cannot be surgically removed. About 10 adults with unresectable hepatocellular carcinoma will re…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lung cancer drug trial halted: olaparib shows no clear benefit in maintenance therapy
Disease control Stopped earlyThis study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy-Chemo cocktail tested for head and neck cancer – early trial stopped
Disease control Stopped earlyThis early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the ri…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cancer combo trial halted early – what went wrong?
Disease control Stopped earlyThis phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Cancer drug combo trial halted early – what we know
Disease control Stopped earlyThis trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for kids with tough neuroblastoma? trial tests stronger therapies
Disease control Stopped earlyThis phase 2 trial tested two stronger treatment plans for children with very high risk neuroblastoma whose cancer did not respond well to initial chemotherapy. The treatments combined radioactive therapy (mIBG), chemotherapy drugs (topotecan and thiotepa), and a stem cell transp…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 26, 2026 13:21 UTC
-
Lung cancer imaging study halted early
Knowledge-focused Stopped earlyThis pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Quick immune boost before breast cancer surgery: does it work?
Knowledge-focused Stopped earlyThis study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The …
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC